Risks

Rarely, focused ultrasound surgery results in:

  • Burns to the skin on your abdomen
  • Damage to tissues and structures near the fibroid targeted for treatment
  • Nerve stimulation causing temporary back or leg pain after the procedure
  • Blood clots in your legs (deep vein thrombosis)

Other drawbacks specific to focused ultrasound surgery include:

  • Less long-term data on safety and effectiveness than most other fibroid treatments
  • Less data on fertility and pregnancy than with other fibroid treatments

As with many other fibroid treatments, when you have focused ultrasound surgery:

  • You may have some fibroids that may not be able to be treated
  • You may require further treatment if your symptoms return
April 30, 2016
References
  1. Zupi E, et al. Nonsurgical alternatives for uterine fibroids. Best Practice and Research Clinical Obstetrics and Gynaecology. In press. Accessed March 20, 2016.
  2. Kong CY, et al. MRI-guided focused ultrasound surgery for uterine fibroid treatment: A cost-effective analysis. American Journal of Roentgenology. 2014;203:361.
  3. Jacoby VL, et al. PROMISe trial: A pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroids. Fertility and Sterility. 2016;105:773.
  4. Magnetic resonance imaging (MRI): Body. RadiologyInfo.org. http://www.radiologyinfo.org/en/info.cfm?pg=bodymr. Accessed March 20, 2016.
  5. Kim HK, et al. Three cases of complications after high-intensity focused ultrasound treatment in unmarried women. Obstetrics and Gynecology Science. 2015;58:542.
  6. Mindjuk I, et al. MRI predictors of clinical success in MR-guided focused ultrasound (MRgFUS) treatments of uterine fibroids: Results from a single centre. European Radiology. 2015;25:1317.
  7. Stewart EA. Uterine fibroids. New England Journal of Medicine. 2015;372:1646.
  8. Coakley FV, et al. Pelvic applications of MR-guided high intensity focused ultrasound. Abdominal Imaging. 2013;38:1120.
  9. Stewart EA (expert opinion). Mayo Clinic, Rochester, Minn. April 1, 2016.